Press

On this press information page you will find the latest press releases and publications of Cytosorbents.

CytoSorbents Announces Positive Surgical Outcomes From CytoSorb Removal Of Antithrombotics In Emergency Cardiothoracic Surgery

07.10.2019

MONMOUTH JUNCTION, N.J., October 7, 2019 — CytoSorbents Corporation (NASDAQ: CTSO), a leader using its CytoSorb® blood purification technology to treat life-threatening medical and surgical conditions around the world, announces positive surgical outcomes in a recent publication entitled, “CytoSorb Adsorption During Emergency Cardiac Operations in Patients at High Risk of Bleeding,” in the journal Annals of Thoracic Surgery, ahead of the European Association of Cardio-thoracic Surgery Annual Meeting in Lisbon, Portugal, October 3-5, 2019.

more…

CytoSorbents Highlights Survival Benefit of CytoSorb Therapy in Septic Shock

30.09.2019

MONMOUTH JUNCTION, N.J., September 24, 2019 — CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, highlights a new publication entitled, “Hemoadsorption with CytoSorb shows a decreased observed versus expected 28-day all-cause mortality in ICU patients with septic shock: a propensity-score-weighted retrospective study,” in the journal Critical Care.

more…

CytoSorbents Receives Renewal of CytoSorb® CE Mark Through May 2024 and Annual ISO 13485:2016 Certification Through September 2022

15.08.2019

MONMOUTH JUNCTION, N.J.Aug. 15, 2019 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that CytoSorb has received renewal of its European Union CE Mark through May 2024and ISO 13485:2016 Full Quality Assurance System certification of its manufacturing facility through September 2022.more…

CytoSorbents Expands CytoSorb Distribution in Latin America to Brazil, Colombia, and Costa Rica

13.08.2019

MONMOUTH JUNCTION, N.J.Aug. 13, 2019 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, expands CytoSorb distribution to BrazilColombia and Costa Rica, with Contatti MedicalService & Medical Colombia, and Nutricare Costa Rica, respectively.more…

Terumo Cardiovascular Group and CytoSorbents Announce CytoSorb Cardiac Surgery Partnership

12.09.2016

Agreement brings innovative anti-inflammatory treatment to cardiac surgery teams in six European countries

ANN ARBOR, MI, and MONMOUTH JUNCTION, NJ, SEPTEMBER 12, 2016 – Terumo Cardiovascular Group, a global leader in medical devices for cardiac and vascular surgery and subsidiary of Japan-based Terumo Corporation (TSE: 4543), and CytoSorbents Corporation (NASDAQ: CTSO), manufacturer of the CytoSorb® extracorporeal blood purification adsorber that reduces excessive levels of inflammatory mediators in critically-ill and cardiac surgery patients, announced today that they have entered into a multi-country strategic partnership to commercialize CytoSorb for cardiac surgery applications.more…

This Blood Filtering System Could Help Lower The Risk of Death From Inflammatory Infections

28.08.2016

Trauma to the body comes in many forms – severe burns, gun shot wounds, liver failure, drug overdose, sepsis – which can be deadly. Treating these types of trauma to the body means people end up in the intensive care unit (ICU).

The overall coast of ICU care in the US has doubled in the past ten years to $108 billion. Sepis, is one of the primary cause of death from infection in ICU.

Dr. Neil Halpern, Chief of the Critical Medicine Service and Medical Director of Respiratory Therapy at Memorial Sloan Kettering, New York, says technology plays a key role in keeping patients with sepsis and other critical illnesses alive in the ICU.more…

view source

CytoSorbents Announces FDA Approval to Commence Initial U.S. Cardiac Surgery Study

February 2nd, 2015

MONMOUTH JUNCTION, N.J., Feb. 2, 2015 /PRNewswire/ — CytoSorbents Corporation (NASDAQ CM: CTSO), a critical care immunotherapy company commercializing its CytoSorb® extracorporeal cytokine adsorber to treat critically-ill and cardiac surgery patients in multiple countries worldwide, announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational Device Exemption (IDE) application to commence a planned U.S. cardiac surgery feasibility study. more…

view source

Innovations in medicine: The stabilizer

spiegel.de, 5.01.2015

from Christian Heinrich

Blood poisoning is the third leading cause of death in Germany. Using a new cylindrical apparatus doctors could potentially save more people. Episode one of our series on medical innovations.

more…

view source

Prince William presents Great Tech award

9.12.2014

Prince William, Duke of Cambridge presents an award to Dr. Phillip Chan, CEO of CytoSorbents Corporation during the Innovation is GREAT Reception at Shutterstock headquarters in the Empire State Building on December 9, 2014 in New York City. The reception was technology themed and the winners of the GREAT Tech Awards were presented with trophies. New York City Mayor Bill De Blasio and British Consul General, New York Danny Lopez also congratulated Dr. Chan and the other winners of the award.

more…

view source

Global threat to humanity

welt.de 13.9.2014

from Erik Klapp

On September 13, doctors all over the world celebrate the World Sepsis Day – and for the first time have hope for a cure: A new medical technology can stop the deadly disease.
more…

view source